[PubMed] [Google Scholar] 14
[PubMed] [Google Scholar] 14. organizations: Group A in whom IABP received before PCI (= 106) and Group B in whom IABP received after PCI (=… Read More »[PubMed] [Google Scholar] 14
[PubMed] [Google Scholar] 14. organizations: Group A in whom IABP received before PCI (= 106) and Group B in whom IABP received after PCI (=… Read More »[PubMed] [Google Scholar] 14
Nat Rev Mol Cell Biol 9:1004C1010. N-linked glycan armor, which covers almost the entire envelope protein (Env) (6, 7). An alternative is to use bNAbs… Read More »Nat Rev Mol Cell Biol 9:1004C1010
Clinically, ganetespib shows a good safety profile with no dose-limiting liver organ or ocular toxicities connected with other Hsp90 inhibitors [20,21], and shows encouraging activity… Read More »Clinically, ganetespib shows a good safety profile with no dose-limiting liver organ or ocular toxicities connected with other Hsp90 inhibitors [20,21], and shows encouraging activity within a Phase 2 NSCLC trial [22]